Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

1-15. (Canceled)

16. (New) A method for treating at least one autoimmune condition in a human subject, said method comprising administering to said subject a therapeutically effective amount of at least one antagonist that binds with a 40 kD subunit, wherein said antagonist is chosen from at least one antibody immunoreactive with the 40 kD subunit and at least one antibody fragment immunoreactive with the 40 kD subunit.

17. (New) The method of claim 16, wherein the antibody that binds to IL-12, binds to an epitope on a 40 kD subunit of IL-12.

18. (New) The method of claim 16, wherein the antibody is a monoclonal antibody.

19. (New) The method of claim 16, wherein the antibody is a polyclonal antibody.

20. (New) The method of claim 16, wherein the 40 kD subunit is disulfide-bonded to the 35 kD subunit of IL-12.

21. (New) The method of treating at least one autoimmune condition of claim 16, wherein the antagonist either

(a) blocks the formation of a heterodimer containing the 40 kD subunit; or

(b) allows the formation of a heterodimer containing the 40 kD subunit, but blocks the activity of said heterodimer.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

22. (New) The method of claim 21, wherein the autoimmune condition is chosen from multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, autoimmune pulmonary inflammation, Guillain-Barre syndrome, autoimmune thyroiditis, insulin dependent diabetes mellitus, and autoimmune inflammatory eye disease.

23. (New) The method of claim 21, wherein the autoimmune condition is insulin dependent diabetes mellitus.

24. (New) The method of claim 21, wherein the autoimmune condition is systemic lupus erythematosus.

25. (New) A method for treating at least one autoimmune condition in a human subject, said method comprising administering to said subject a therapeutically effective amount of at least one antagonist that binds with the 35 kD subunit, wherein said antagonist is chosen from at least one antibody immunoreactive with the 35 kD subunit and at least one antibody fragment immunoreactive with the 35 kD subunit.

26. (New) The method of claim 25, wherein the antibody that binds to IL-12, binds to an epitope on a 35 kD subunit of IL-12.

27. (New) The method of claim 25, wherein the antibody is a monoclonal antibody.

28. (New) The method of claim 25, wherein the antibody is a polyclonal antibody.

29. (New) The method of claim 25, wherein the 35 kD subunit is disulfide-bonded to the 40 kD subunit of IL-12.

30. (New) The method for treating at least one autoimmune condition of claim 25, wherein the antagonist either

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

(a) blocks the formation of a heterodimer containing the 35 kD subunit; or

(b) allows the formation of a heterodimer containing the 35 kD subunit, but blocks the activity of said heterodimer.

31. (New) The method of claim 30, wherein the autoimmune condition is chosen from multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, autoimmune pulmonary inflammation, Guillain-Barre syndrome, autoimmune thyroiditis, insulin dependent diabetes mellitus, and autoimmune inflammatory eye disease.

32. (New) The method of claim 30, wherein the autoimmune condition is insulin dependent diabetes mellitus.

33. (New) The method of claim 30, wherein the autoimmune condition is systemic lupus erythematosus.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com